,

SERPINx participates at BioEurope Spring in Vienna, Austria

SERPINx will be present at the upcoming 13th annual BioEurope Spring partnering conference, March 25th to March 27th in Vienna, Austria.

SERPINx will be meeting with investors and service providers during the BioEurope Spring to initiate further development and seed/series A funding for their lead compound SPx-001 as a gene therapy for Heriditary Angioedema. We would be happy to meet with you in Vienna.

More info: https://ebdgroup.knect365.com/bioeurope-spring/

 

SERPINx participates in Bradykinin Symposium Berlin

SERPINx will be present at the upcoming 5th Bradykinin Symposium, September 5th to September 7th in Berlin, Germany. 

International experts in the field of bradykinin have been invited to discuss the role of bradykinin and the contact system in health and disease. Meet SERPINx at the 5th Bradykinin Symposium taking place in Berlin.

https://www.bradykinin-symposium.de/programme/bradykinin-symposium/

SERPINx present at KININ conference in Cleveland, Ohio

SERPINx will be presenting at the upcoming KININ2018CLE conference, June 17th to June 20th in Cleveland, Ohio. Kinin 2018 CLE is organized by Case Western Reserve University School of Medicine (CWRU) and will be held during Jun 17 – 20, 2018 at Tinkham Veale University Center, Cleveland, Ohio, United States of America.

The KININ meeting occurs every three years, assembling scientists and clinicians involved in the field of bradykinin (kinins) and its related proteins (enzymes, cofactors, substrates, receptors, proteolytic systems, disease states, and developing therapies) for presentation of the latest ideas, research, drug development and therapeutics in these biologic systems. The 2018 event will focus on contact, kallikrein/kinin, and complement proteins in hereditary angioedema and thrombosis and their developing therapies, kinin receptors in disease, kinin receptor interaction with receptors of the renin-angiotensin system, the influence of the renin angiotensin system with bradykinin and its receptors’ biology, and the influence of this overall system in vascular biology, diabetes, hypertension, heart failure and other related disease states.

Gordon Research Conference

The KININ meeting is organized like a Gordon Research Conference whereby for each topic, 3-4 individuals will be invited for presentations. Each session, however, will also leave open time for oral presentations from the best abstracts submitted. Junior investigators in the fields are encouraged to submit their work for presentation. Travel awards are available for predoctoral and postdoctoral fellows and junior faculty whose work is chosen for oral presentation and poster awards. There will be six scientific sessions, two per day. A poster viewing session will be organized daily. In addition, several social events will be organized for participants to gather together and enjoy some of the highlights of Cleveland, Ohio.

Conference Objectives are :
• To bring together the world’s best investigators in the field of kinins for sharing research and generation of new ideas for future investigation
• To emphasize those areas where kinin science is now being translated into clinical use; and
• To inspire the next generation of investigators in this field to achieve that which their teachers and mentors were unable to accomplish.

Meet SERPINx at the KININ2018CLE in Cleveland, Ohio.

Program: https://www.uhdoctor.org/kinin2018cle-program

SERPINx closes agreement with UMC Utrecht

UTRECHT, THE NETHERLANDS, November 20, 2017 – SERPINx B.V., a Dutch protein therapeutics company involved in developing novel serine protease inhibitor (serpin) therapeutics for inflammatory-associated diseases, announces that it has closed its patent and know how licence and assignment option agreement with University Medical Center Utrecht (UMC Utrecht).

SERPINx  BV is a Dutch protein therapeutics company involved in developing novel  serine protease inhibitor (serpin) therapeutics for inflammatory-associated diseases, in particular angioedema. It is our goal to transform excellent and promising research output into novel high-value therapeutics that serve angioedema patients.

For more information on U-PACT, please contact Dr. Martin Hessing (CEO): M.Hessing@SERPINx.com

SERPINx B.V. receives Take-off grant from NWO

SERPINx B.V., a biotherapeutic company that develops novel SERPINs to inhibit bradykinin mediated diseases, has received the Take-off fase 1 grant from NWO-TTW.

The feasibility grant entitled ‘Designer SERPINs for treatment of inflammatory disease’ of 40,000 euro will be used to launch the company and start the pre-clinical development program for its mutant alpha1-antitrypsin lead compound SERPIN1 for idiopathic angioedema. For more information on SERPINx B.V., please contact Dr. Martin Hessing, CEO at m.hessing@serpinx.com